Unfractionated Heparin for the Treatment of Venous Thromboembolism: Best Practices and Areas of Uncertainty

2012/06/20 by Adam Cuker · 1 citation
Medicine · #Venous Thromboembolism Diagnosis and Management #Atrial Fibrillation Management and Outcomes #Blood Coagulation and Thrombosis Mechanisms

paper · doi:10.1055/s-0032-1319770

Abstract

Nearly 100 years after its discovery, unfractionated heparin (UFH) remains a widely used anticoagulant for the treatment of venous thromboembolism (VTE) and several other thrombotic and prothrombotic conditions. Decades of experience and investigation have contributed to our knowledge of this agent, but crucial questions regarding its optimal use in clinical practice remain unanswered. This review will critically examine the evidence for dosing and laboratory monitoring of UFH in the management of VTE, and highlight areas of uncertainty and future research.

Cited by

• Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy

Related

• Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy
• A Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism
• Role of Thrombophilia in Deciding on the Duration of Anticoagulation
• Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: The Last 10 Years
• Scoring Systems for Estimating Risk of Venous Thromboembolism in Hospitalized Medical Patients